Organizer: CTAD (Clinical Trials on Alzheimer's Disease)
Website: ctad-alzheimer.com
Typical Timing: October/November annually
CTAD (Clinical Trials on Alzheimer's Disease) is the premier international conference focused specifically on clinical trials for Alzheimer's disease and related dementias. Founded in 2008, CTAD has become the most important venue for presenting late-breaking clinical trial results, discussing novel trial designs, and shaping the future of Alzheimer's therapeutics development.
Unlike general neurology meetings that cover a broad range of topics, CTAD exclusively addresses the design, execution, and analysis of clinical trials in the Alzheimer's field. This focused approach makes CTAD the most targeted venue for AD clinical research, attracting key stakeholders including academic researchers, pharmaceutical companies, regulatory agencies (FDA, EMA), and patient advocacy organizations.
CTAD features extensive coverage of innovative clinical trial methodologies:
- Platform Trials: Umbrella and platform trial designs enabling multiple treatments to be tested simultaneously under a single protocol
- Adaptive Designs: Group sequential designs, sample size re-estimation, and adaptive randomization approaches that allow for modifications during trials
- Enrichment Strategies: Biomarker-enriched populations and genetic stratification approaches to identify patients most likely to respond
- Endpoint Optimization: Clinical outcome assessment validation and digital endpoint development for more sensitive detection
- Statistical Methods: Novel approaches to analyzing cognitive and functional outcomes in diverse populations
The conference covers the full spectrum of therapeutic modalities:
- Disease-Modifying Therapies: Anti-amyloid, anti-tau, and neuroprotective agents targeting underlying disease processes
- Symptomatic Treatments: Cognitive enhancers, behavioral interventions, and novel symptomatic approaches
- Prevention Trials: Trials in pre-symptomatic and prodromal populations to delay or prevent disease onset
- Combination Therapies: Multi-target approaches for synergistic effects on disease progression
- Repurposed Drugs: Existing medications being evaluated for Alzheimer's including diabetes drugs, statins, and anti-inflammatories
Biomarker development and validation is a major focus:
- Fluid Biomarkers: Blood-based tests for amyloid, tau, and neurodegeneration including p-tau217, p-tau181, and GFAP
- Imaging Biomarkers: PET, MRI, and novel imaging techniques for detecting pathology in vivo
- Digital Biomarkers: Remote monitoring and passive data collection through wearables and smartphones
- Composite Biomarker Panels: Multi-marker approaches for patient stratification and treatment selection
CTAD provides a unique forum for regulatory dialogue:
- FDA Sessions: Regulatory perspectives on trial design and approval pathways
- EMA Workshops: European regulatory considerations and harmonization efforts
- Global Harmonization: International regulatory alignment efforts across jurisdictions
- Accelerated Approval: Pathways for conditional approvals based on biomarker endpoints
The past two years have witnessed unprecedented progress in Alzheimer's therapeutics:
- Lecanemab (Leqembi): Full approval following CLARITY-AD trial demonstrating 27% slowing of cognitive decline
- Donanemab: TRAILBLAZER-ALZ 2 results showing disease modification in early AD
- Anti-tau Therapies: Multiple tau-targeting agents advancing in clinical trials
- Blood Biomarkers: Emergence of p-tau217 as a practical diagnostic tool
The focus is shifting toward:
- Combination Therapies: Testing multiple mechanisms simultaneously to achieve greater efficacy
- Earlier Intervention: Trials in pre-symptomatic populations to prevent neurodegeneration
- Personalized Medicine: Genetic and biomarker-guided treatment selection
- Better Outcomes: Novel endpoints capturing clinically meaningful benefits
- Late-Breaking Results: Platform presentations of primary trial endpoints
- Symposia: Invited sessions on specialized topics
- Workshops: Hands-on training in trial methodology
- Poster Sessions: Original research presentations
- Regulatory Roundtables: Interactive discussions with regulators
- Industry Forums: Company presentations on pipeline programs
- Day 1: Workshops, early career events, industry symposia
- Day 2-3: Main platform sessions, symposia, poster sessions
- Day 4: Late-breaking abstracts, regulatory sessions, closing
CTAD has been instrumental in advancing Alzheimer's clinical research:
- Trial Standardization: Established common endpoints and methodologies across studies
- Regulatory Dialogue: Facilitated productive FDA/EMA engagement and alignment
- International Collaboration: Connected researchers globally to accelerate progress
- Patient Advocacy: Integrated patient perspectives in trial design
- Education: Trained next generation of clinical trialists through workshops
- 2008: First CTAD held in Monte Carlo
- 2012: Growth to 1,000+ attendees
- 2015: Introduction of late-breaking abstract sessions
- 2019: Record attendance of 3,000+
- 2020: First virtual CTAD during pandemic
- 2022: Lecanemab CLARITY-AD results presented
- 2023: Multiple drug approvals transform landscape